FDA Approves Boxed Warning About Increased Risk of Blood Clots and Death with Higher Dose of Tofacitinib (Xeljanz, Xeljanz XR)
Audience: Consumer, Health Professional, Pharmacy
July 26, 2019 -- The U.S. Food and Drug Administration has approved new wa
HbA1c, BMI Linked to Stillbirth Risk in Women With Diabetes
FRIDAY, Aug. 9, 2019 -- Higher maternal hemoglobin A1c (HbA1c) levels are associated with increased risk for stillbirth among women with type 1 diabetes, while higher BMI increases risk for wome
Jubilant Cadista Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, Due to Out-of-Specification Dissolution Test Results
Audience: Consumer, Health Professional, Pharmacy
July 23, 2019 -- Salisb
Estrogen Preps Differ in Effects on Heart Fat Deposits
FRIDAY, Aug. 2, 2019 -- Hormone therapy formulations have differential effects on heart fat deposits in early menopausal women, according to a study published online Aug. 1 in the Journal of the Amer
Health Tip: Living With Hypoglycemia
-- Hypoglycemia occurs when your blood sugar is too low, says the Hormone Health Network.
People with diabetes often develop hypoglycemia, but it is possible for people without diabetes to become hypoglycemic, as w
FDA Approves Nubeqa
FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer
WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an